<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6244">
  <stage>Registered</stage>
  <submitdate>17/12/2014</submitdate>
  <approvaldate>17/12/2014</approvaldate>
  <nctid>NCT02322229</nctid>
  <trial_identification>
    <studytitle>Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion</studytitle>
    <scientifictitle>Assessment of Anatomical and Functional Outcomes in Subjects Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-004778-41</secondaryid>
    <secondaryid>RTA255-P001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Vitreomacular Traction</healthcondition>
    <healthcondition>Vitreomacular Adhesion</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ocriplasmin 0.125 mg in a 0.1 mL volume

Experimental: Ocriplasmin - Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal (IVT) injection


Treatment: drugs: Ocriplasmin 0.125 mg in a 0.1 mL volume


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of subjects with non-surgical resolution of focal VMT/sVMA at Day 28, as determined by Central Reading Center (CRC) Spectral Domain Optical Coherence Tomography (SD-OCT) evaluation</outcome>
      <timepoint>Day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in best-corrected visual acuity (BCVA) at distance at Days 7, 28, 90, and 180</outcome>
      <timepoint>Baseline (Day 0), Up to Day 180</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with closure of macular hole (MH), at Days 7, 28, 90, and 180 (if present at baseline)</outcome>
      <timepoint>Up to Day 180</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with non-surgical resolution of VMT/sVMA at Days 7, 90, and 180</outcome>
      <timepoint>Up to Day 180</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects experiencing Pars plana vitrectomy (PPV) at Day 180</outcome>
      <timepoint>Day 180</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in central foveal thickness at Days 28 and 180</outcome>
      <timepoint>Baseline (Day 0), Up to Day 180</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of VMT/sVMA, with evidence of focal VMT visible on Spectral Domain - Optical
             Coherence Tomography (SD-OCT).

          -  Read, sign, and date an Institutional Review Board/Ethics Committee-approved informed
             consent form.

          -  Willing and able to attend all study visits.

          -  Other protocol-specified inclusion criteria may apply.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Women of childbearing potential if pregnant, test positive on a urine pregnancy test,
             intend to become pregnant during the study period, breastfeeding, or not in agreement
             to use adequate birth control methods to prevent pregnancy throughout the study.

          -  Hypersensitivity to ocriplasmin or any of the JETREA excipients.

          -  Active or suspected intraocular or periocular infection in either eye.

          -  Participation in any interventional clinical trial within 30 days prior to baseline.

          -  Presence of epiretinal membrane (ERM) over the central macula in the study eye.

          -  Broad VMT/sVMA &gt; 1500 microns in the study eye.

          -  History of vitrectomy in the study eye.

          -  History of laser photocoagulation to the macula in the study eye.

          -  Any relevant concomitant ocular condition in the study eye that, in the opinion of the
             Investigator, could be expected to worsen or require surgical intervention during the
             study period.

          -  Macular hole of &gt; 400 microns diameter in the study eye.

          -  High myopia in the study eye.

          -  Pseudo-exfoliation, Marfan's syndrome, phacodonesis, or any other finding in the study
             eye that, in the Investigator's opinion, suggests lens/zonular instability.

          -  Aphakia in the study eye.

          -  History of retinal detachment in the study eye.

          -  Recent ocular surgery or ocular injection in the study eye within the past 90 days
             (including laser therapy).

          -  Proliferative diabetic retinopathy or ischemic retinopathies in the study eye.

          -  Retinal vein occlusions in the study eye.

          -  Exudative age-related macular degeneration (AMD) in the study eye.

          -  Vitreous hemorrhage in the study eye.

          -  Other protocol-specified exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>62</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Contact Alcon Laboratories (Australia) for Trial Locations - New South Wales</hospital>
    <postcode>2113 - New South Wales</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alcon Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin
      (JETREAÂ®) over a 6-month follow-up period.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02322229</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sr Clinical Manager, GCRA, Global Med Affairs</name>
      <address>Alcon Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>